Rest energy expenditure in Parkinson's disease: role of disease progression and dopaminergic therapy

Parkinsonism Relat Disord. 2013 Feb;19(2):238-41. doi: 10.1016/j.parkreldis.2012.10.016. Epub 2012 Nov 20.

Abstract

Background: Weight loss affects more than 50% of subjects suffering from Parkinson's Disease (PD) and is associated with reduced life expectancy. The pathogenesis is multifactorial and the mechanism of PD metabolism control is unresolved. This cross-sectional study aimed to ascertain the relationship between rest energy expenditure (REE), PD duration, Hoehn & Yahr (H&Y) stage, drug therapy and body mass index (BMI), in order to determine possible predictors of weight loss.

Methods: We studied fifty-eight PD subjects, after excluding conditions with a known influence on metabolism and weight (severe tremor, dyskinesias, dementia, fever, on-going infections, thyroid disease, and dysphagia). Subjects underwent REE measurement, through indirect calorimetry, in both the OFF state (12 h fasting and off medications) and in the ON state (60 min after taking dopaminergic drugs).

Results: OFF state. In the majority of PD patients REE values did not differ from those expected (based upon age, gender and BMI), being significantly higher in subjects in H&Y stage IV than H&Y stage II (t = 3.5; p = 0.001). Disease duration and rigidity were significantly associated with increased REE (r(2) = 0.31, F = 3.6; p = 0.0045). ON state. REE decreased by approximately 8% in all subjects, irrespective of disease duration or H&Y stage. BMI was inversely related to disease duration and UPDRS motor score in the OFF state and directly related to UPDRS motor score in the ON state (r(2) = 0.333, F = 3.5; p = 0.003).

Conclusions: In PD REE increases as a function of disease duration; its adverse role in the decrease in BMI seems to be compensated for by dopaminergic medication.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antiparkinson Agents / therapeutic use*
  • Body Mass Index
  • Calorimetry, Indirect
  • Cross-Sectional Studies
  • Disease Progression
  • Energy Metabolism / drug effects
  • Energy Metabolism / physiology*
  • Female
  • Humans
  • Male
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology*
  • Rest / physiology*

Substances

  • Antiparkinson Agents